Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAB Atlantic Coastal Acquisition Corp. II	$5.77 -47.1%	$8.44	$5.75 ▼ $13.00	$47.14M	0.01	9,443 shs	162,400 shs
CDTX Cidara Therapeutics	$22.02 -3.0%	$20.74	$10.14 ▼ $28.42	$276.29M	0.86	79,792 shs	111,906 shs
GOSS Gossamer Bio	$1.13 -2.6%	$1.01	$0.50 ▼ $1.55	$256.85M	1.82	1.54 million shs	1.00 million shs
YMAB Y-mAbs Therapeutics	$4.75 +2.8%	$4.38	$3.55 ▼ $16.11	$215.10M	0.53	310,130 shs	302,142 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAB Atlantic Coastal Acquisition Corp. II	0.00%	0.00%	0.00%	0.00%	-46.57%
CDTX Cidara Therapeutics	-2.95%	-14.32%	+4.26%	-11.57%	+86.29%
GOSS Gossamer Bio	-2.59%	-2.59%	+28.16%	-8.13%	+93.46%
YMAB Y-mAbs Therapeutics	+2.81%	+15.01%	+13.10%	-14.51%	-61.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	4.3069 of 5 stars	4.6	3.0	0.0	4.6	2.2	0.8	0.0
GOSS Gossamer Bio	3.9447 of 5 stars	3.5	2.0	0.0	4.7	3.1	1.7	0.0
YMAB Y-mAbs Therapeutics	3.7562 of 5 stars	4.4	2.0	0.0	0.0	3.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAB Atlantic Coastal Acquisition Corp. II	0.00	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.22	Buy	$41.86	90.09% Upside
GOSS Gossamer Bio	3.00	Buy	$7.75	585.84% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	228.42% Upside

Current Analyst Ratings Breakdown

Latest ACAB, CDTX, YMAB, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	$302K	914.85	N/A	N/A	($1.82) per share	-12.10
GOSS Gossamer Bio	$124.59M	2.06	N/A	N/A	$0.28 per share	4.04
YMAB Y-mAbs Therapeutics	$88.66M	2.43	N/A	N/A	$2.32 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/11/2025 (Estimated)
GOSS Gossamer Bio	-$179.82M	-$0.23	N/A	N/A	N/A	N/A	-127.28%	-22.12%	8/11/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.64	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	8/11/2025 (Estimated)

Latest ACAB, CDTX, YMAB, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
3/18/2025	Q4 2024	GOSS Gossamer Bio	-$0.15	-$0.15	N/A	-$0.15	$7.02 million	$9.38 million
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	3.54	3.54
GOSS Gossamer Bio	3.64	6.74	6.74
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAB Atlantic Coastal Acquisition Corp. II	23.30%
CDTX Cidara Therapeutics	35.82%
GOSS Gossamer Bio	81.23%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ACAB Atlantic Coastal Acquisition Corp. II	91.19%
CDTX Cidara Therapeutics	7.64%
GOSS Gossamer Bio	6.70%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAB Atlantic Coastal Acquisition Corp. II	4	8.17 million	720,000	Not Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
GOSS Gossamer Bio	180	227.30 million	215.27 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

ACAB, CDTX, YMAB, and GOSS Headlines

Recent News About These Companies

Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29 at 12:09 PM | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29 at 12:09 PM | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Outperform" Rating at Wedbush

May 29 at 2:23 AM | americanbankingnews.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28 at 6:35 AM | globenewswire.com

Infinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 28 at 6:10 AM | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.com

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

HC Wainwright Brokers Decrease Earnings Estimates for YMAB

May 23, 2025 | marketbeat.com

HC Wainwright Brokers Reduce Earnings Estimates for YMAB

May 23, 2025 | americanbankingnews.com

FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Has $4.82 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 20, 2025 | marketbeat.com

HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00

May 20, 2025 | americanbankingnews.com

Wedbush Cuts Earnings Estimates for Y-mAbs Therapeutics

May 17, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

May 17, 2025 | marketbeat.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Paradigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 16, 2025 | marketbeat.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAB, CDTX, YMAB, and GOSS Company Descriptions

Atlantic Coastal Acquisition Corp. II NASDAQ:ACAB

Atlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in financial services industry and mobility sector. The company was incorporated in 2021 and is based in New York, New York. Atlantic Coastal Acquisition Corp. II is a subsidiary of Atlantic Coastal Acquisition Management II LLC.

Cidara Therapeutics NASDAQ:CDTX

$22.02 -0.67 (-2.95%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$21.53 -0.49 (-2.22%)

As of 05/29/2025 07:31 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$1.13 -0.03 (-2.59%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.03 (+2.65%)

As of 04:00 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.75 +0.13 (+2.81%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.16 (-3.37%)

As of 04:38 AM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time